Serum Elabela Level as a Reliable Biomarker for Predicting of Liver Fibrosis in Iraqi Patients with Chronic Hepatitis C

Serum Elabela Level as a Reliable Biomarker for Predicting of Liver Fibrosis in Iraqi Patients with Chronic Hepatitis C

Background:Elabela is a newly discovered peptide hormone that has been implicated in liver disease. Objective:The main objective of the current work is to assess whether variations in blood Elabela levels among chronic hepatitis C (CHC) patients from Iraq might be used as a biomarker for liver fibro...

Full description

Saved in:

Bibliographic Details
Main Authors:	Eham Amer Ali, Ali Abdulateef Hasan Al-Bayati, Alea Farhan Salman
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-07-01
Series:	Medical Journal of Babylon
Subjects:	apri chronic hepatitis c elabela liver fibrosis
Online Access:	https://journals.lww.com/10.4103/MJBL.MJBL_666_23
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The potential of serum elabela levels as a marker of diabetic retinopathy: results from a pilot cross-sectional study
by: Muhammed Seyithanoğlu, et al.
Published: (2025-01-01)

Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-γ /FDX1 signaling
by: Rui-Qiang Qi, et al.
Published: (2024-11-01)

ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
by: Jing-Yu Hou, et al.
Published: (2025-02-01)

Magnoflorine ameliorates hepatic fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway
by: Meiling Zhang, et al.
Published: (2024-11-01)

The validity of serum autotaxin as a predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease
by: Muhammad Abdel-Gawad, et al.
Published: (2023-10-01)

Differential effects of systemic immune inflammation indices on hepatic steatosis and hepatic fibrosis: evidence from NHANES 1999–2018
by: Shuyin Duan, et al.
Published: (2024-12-01)

Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances
by: Liangtao Zhao, et al.
Published: (2024-12-01)

Role of aspartate aminotransferase to platelet ratioin prediction of intrahepatic cholestasis of pregnancy
by: Nizamettin Bozbay, et al.
Published: (2024-12-01)

Analysis of the Relationship between ALBI Score and APRI Score on Severity, Length of Treatment and Mortality in COVID-19 Patients at Dr. Saiful Anwar Hospital, Malang
by: Bogi Wibowo, et al.
Published: (2024-11-01)

Assessment of hepatic fibrosis in patients with rheumatoid arthritis on long-term methotrexate therapy using transient elastography
by: Abhishek Kumar, et al.
Published: (2018-01-01)

Antiviral therapy and regression of liver fibrosis at chronic hepatitis B
by: D. T. Abdurakhmanov
Published: (2010-02-01)

Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis
by: Jonghyun Kim, et al.
Published: (2024-11-01)

Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B
by: Ye Ji Jun, et al.
Published: (2024-11-01)

THE COURSE OF HEPATITIS C INFECTION AND RESPONSE TO ANTI-VIRAL THERAPY IN PATIENTS WITH THALASSEMIA MAJOR AND HEPATITIS C INFECTION: A LONGITUDINAL, PROSPECTIVE STUDY.
by: Sanaa Kamal, et al.
Published: (2019-10-01)

Amygdalin isolated from Amygdalus mongolica protects against hepatic fibrosis in rats
by: Wang Jia, et al.
Published: (2021-09-01)

Effect of SARS-CoV-2 Infection on Selected Parameters of the Apelinergic System in Repeat Blood Donors
by: Marta Stanek, et al.
Published: (2024-11-01)

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B
by: Gi-Ae Kim, et al.
Published: (2024-10-01)

Noninvasive diagnosis of significant liver fibrosis in patients with chronic hepatitis B using nomogram and machine learning models
by: Chuan Jiang, et al.
Published: (2025-01-01)

Multi-target regulatory effects of rhaponticin in a rat model of hepatic fibrosis revealed by non-targeted metabolomics
by: Min Yang, et al.
Published: (2025-01-01)

Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients
by: Mohamed El-Kassas, et al.
Published: (2024-11-01)

Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study
by: Xiaohui Fang, et al.
Published: (2024-11-01)

Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy
by: K. R. Dudina, et al.
Published: (2023-02-01)

Pathological Microenvironment‐Remodeling Nanoparticles to Alleviate Liver Fibrosis: Reversing Hepatocytes‐Hepatic Stellate Cells Malignant Crosstalk
by: Ling‐Feng Zhang, et al.
Published: (2025-01-01)

Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA
by: Jian Wang, et al.
Published: (2024-12-01)

Artesunate: A potential drug for the prevention and treatment from hepatitis to hepatocellular carcinoma
by: Xinyue Liu, et al.
Published: (2024-12-01)

Comparative evaluation of APRI and MELD scores in the prediction of complications of chronic hepatitis in patients infected with hepatitis B or C viruses in Lubumbashi, democratic republic of Congo
by: Arsène Kabamba-Tshikongo, et al.
Published: (2025-02-01)

Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients
by: Qiyao Wei, et al.
Published: (2025-02-01)

Heparan sulfate proteoglycan-mediated internalization of extracellular vesicles ameliorates liver fibrosis by targeting hepatic stellate cells
by: Rongrong Li, et al.
Published: (2022-12-01)

Association of exposure to multiple volatile organic compounds with ultrasound-defined hepatic steatosis and fibrosis in the adult US population: NHANES 2017–2020
by: Wentao Shao, et al.
Published: (2025-01-01)

Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C
by: Yuanji Ma, et al.
Published: (2024-11-01)

Predictors of liver fibrosis changes assessed by paired liver biopsies in chronic hepatitis C patients treated with direct-acting antivirals
by: Ming-Han Hsieh, et al.
Published: (2024-12-01)

Value of autotaxin as a serum marker for liver fibrosis in chronic HCV infected patients receiving direct-acting antiviral therapy
by: Ahmed Moustafa, et al.
Published: (2024-08-01)

OPN‐Mediated Crosstalk Between Hepatocyte E4BP4 and Hepatic Stellate Cells Promotes MASH‐Associated Liver Fibrosis
by: Sujuan Wang, et al.
Published: (2024-12-01)

Non-invasive of liver fibrosis diagnostics: the role of serum markers
by: A. F. Sheptulina, et al.
Published: (2015-05-01)

Seroprevalence of Hepatitis E Virus Among Schistosomiasis mansoni Patients Residing in Endemic Zone in Brazil
by: Cristiane Tiburtino de Oliveira Gomes, et al.
Published: (2024-12-01)

Multi-omics and experimental analysis unveil the key components in Scutellaria baicalensis Georgi to alleviate hepatic fibrosis via regulating cPLA2-mediated arachidonic acid metabolism
by: Yunheng Yang, et al.
Published: (2024-12-01)

Combined metabolomics and 16S rDNA sequence analyses of the gut microbiome reveal the action mechanism of Fructus Akebiae against hepatic fibrosis
by: Rong-Rong Wu, et al.
Published: (2025-02-01)

ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis‐Associated Hepatocellular Carcinoma by Modulating Tumor‐Associated Macrophages
by: Yuyang Du, et al.
Published: (2024-12-01)

Unveiling Prevalence, Risk Factors, and Outcomes of Hepatitis D Among Vulnerable Communities in Romania
by: Liana Gheorghe, et al.
Published: (2024-12-01)

Age-Dependent Effects of Butyl Benzyl Phthalate Exposure on Lipid Metabolism and Hepatic Fibrosis in Mice
by: Min-Seo Park, et al.
Published: (2025-01-01)